- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
Synonyms: MM 121
Seribantumab (Anti-ERBB3 / HER3) is a fully human IgG2 monoclonal antibody that targets HER3. It inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models. MW : 143.14 KD.
| Name | Citation | HER2 | Others |
|---|---|---|---|
| Canertinib (CI-1033) | 48 | EGFR | |
| CP-724714 | 109 | ||
| Sapitinib (AZD8931) | 50 | ErbB3,EGFR | |
| CUDC-101 | 23 | EGFR,HDAC,HDAC1 | |
| Mubritinib (TAK 165) | 40 | ||
| AEE788 (NVP-AEE788) | 13 | EGFR,c-Abl,FLT1 | |
| AC480 (BMS-599626) | 10 | HER1,HER4 | |
| TAK-285 | 4 | EGFR/HER1,HER4,MEK1 | |
| Tyrphostin AG 879 | 3 | Trk | |
| Tuxobertinib (BDTX-189) | 2 | EGFR,RIPK2,BLK | |
| Epertinib hydrochloride | 0 | EGFR,HER4 | |
| TAS0728 | 1 | ||
| Tyrphostin AG-528 | 0 | EGFR | |
| SU5204 | 1 | VEGFR-2 | |
| Pyrotinib dimaleate | 4 | EGFR | |
| Poziotinib (HM781-36B) | 35 | HER1,HER4 | |
| HER2-Inhibitor-1 | 1 | ||
| Zongertinib | 1 | EGFR-Ex20ins | |
| Nordihydroguaiaretic acid (NDGA) | 1 | p300,IGF-1R,lipoxygenase | |
| EGCG ((-)-Epigallocatechin Gallate) | 42 | FASN,EGFR,DNMT |
| Description |
Seribantumab (Anti-ERBB3 / HER3) is a fully human IgG2 monoclonal antibody that targets HER3. It inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models. MW : 143.14 KD.
|
References |
|---|
| CAS No. | 1334296-12-6 |
|---|---|
| Molecular Weight | 143.14 |
| Isotype | Human IgG2SA |
| Source | CHO |
| Purification | AKTA |
| Sterility | 0.2 μM filtered |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage (From the date of receipt) |
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.